AVALO THERAPEUTICS, INC. Disposal Group, Including Discontinued Operation, Other Assets, Noncurrent
AVALO THERAPEUTICS, INC. (AVTX) had Disposal Group, Including Discontinued Operation, Other Assets, Noncurrent of $0 as of 2022-12-31, per its 10-K filed 2023-03-29.
Discontinued › Balance Sheet › Assets › Assets, Noncurrent › Disposal Group, Including Discontinued Operation, Assets, Noncurrent
us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets · last filed 2023-03-29
- 2022-12-31: Disposal Group, Including Discontinued Operation, Other Assets, Noncurrent $0.00.
- 2022-09-30: Disposal Group, Including Discontinued Operation, Other Assets, Noncurrent $0.00.
- 2022-06-30: Disposal Group, Including Discontinued Operation, Other Assets, Noncurrent $0.00.
- 2022-03-31: Disposal Group, Including Discontinued Operation, Other Assets, Noncurrent $1.00M.
| Period end | Disposal Group, Including Discontinued Operation, Other Assets, Noncurrent |
|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-03-29 |
| 2022-09-30 | $0.00 10-Q · filed 2022-11-07 |
| 2022-06-30 | $0.00 10-Q · filed 2022-08-04 |
| 2022-03-31 | $1.00M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $1.00M 10-K · filed 2023-03-29 |
| 2021-09-30 | $2.00M 10-Q · filed 2021-11-09 |
| 2020-12-31 | $0.00 10-K · filed 2022-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |